Tag: Zenosense

Zenosense, Inc.: Update on MIDS Medical Test Strip Development

VALENCIA, SPAIN, March 20, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Zenosense, Inc. (OTCQB: ZENO, “Zenosense”, the “Company”), a healthcare technology company focused on the development and commercialization of the MIDS Cardiac™ hand-held technology for the early detection of heart attack at the Point of Care, is pleased to announce an […]

Zenosense, Inc.: MIDS Medical Expands Technical Team

VALENCIA, SPAIN, Oct. 02, 2018 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Zenosense, Inc. (OTCQB: ZENO, “Zenosense”, the “Company”), a healthcare technology company focused on the development and commercialization of the MIDS Cardiac™ hand-held technology for the early detection of heart attack at the Point of Care, is pleased to announce […]

Zenosense, Inc.: Breakthrough Quantitative MIDS Testing Results

VALENCIA, SPAIN., June 19, 2018 (GLOBE NEWSWIRE) — Zenosense, Inc. (OTC PINK: ZENO) (“Zenosense”, the “Company”), a healthcare technology company focused on the development and commercialization of the MIDS Cardiac™ hand-held technology for the early detection of heart attack at the Point of Care, is pleased to announce that its […]

Zenosense, Inc.: MIDS Shareholder Update

VALENCIA, SPAIN, May 24, 2018 (GLOBE NEWSWIRE) — Zenosense, Inc. (OTC PINK: ZENO) (“Zenosense”, the “Company”), a healthcare technology company primarily focused on the development and commercialization of MIDS Cardiac™, a Point of Care handheld device for the early detection of certain cardiac event biomarkers.  We believe that MIDS Cardiac will […]